| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leiomyoma | 143 | 2024 | 202 | 50.550 |
Why?
|
| Uterine Neoplasms | 121 | 2024 | 247 | 41.860 |
Why?
|
| Menorrhagia | 17 | 2024 | 26 | 9.440 |
Why?
|
| Myometrium | 32 | 2024 | 51 | 7.920 |
Why?
|
| Primary Ovarian Insufficiency | 12 | 2024 | 22 | 6.620 |
Why?
|
| Leiomyosarcoma | 9 | 2024 | 45 | 5.580 |
Why?
|
| Genetic Therapy | 27 | 2016 | 370 | 5.570 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 7 | 2023 | 61 | 4.930 |
Why?
|
| Female | 211 | 2024 | 46202 | 4.510 |
Why?
|
| Polycystic Ovary Syndrome | 10 | 2024 | 206 | 4.460 |
Why?
|
| Adenoviridae | 25 | 2020 | 349 | 4.460 |
Why?
|
| Endocrine Disruptors | 9 | 2023 | 27 | 4.440 |
Why?
|
| Vitamin D | 18 | 2024 | 269 | 3.860 |
Why?
|
| Cell Proliferation | 36 | 2024 | 1652 | 3.830 |
Why?
|
| Catechol O-Methyltransferase | 16 | 2014 | 69 | 3.590 |
Why?
|
| Exosomes | 5 | 2024 | 53 | 3.520 |
Why?
|
| Catechin | 7 | 2024 | 24 | 3.410 |
Why?
|
| Estrogens | 20 | 2024 | 201 | 3.170 |
Why?
|
| Pyrimidinones | 9 | 2024 | 38 | 3.160 |
Why?
|
| Humans | 213 | 2024 | 89357 | 3.130 |
Why?
|
| Infertility | 4 | 2024 | 38 | 2.710 |
Why?
|
| Mediator Complex | 8 | 2024 | 13 | 2.670 |
Why?
|
| Estradiol | 16 | 2024 | 251 | 2.660 |
Why?
|
| Phenylurea Compounds | 7 | 2024 | 115 | 2.660 |
Why?
|
| Endometriosis | 10 | 2024 | 59 | 2.510 |
Why?
|
| Epigenesis, Genetic | 14 | 2024 | 507 | 2.360 |
Why?
|
| Uterine Myomectomy | 4 | 2024 | 10 | 2.300 |
Why?
|
| Leiomyomatosis | 6 | 2021 | 12 | 2.250 |
Why?
|
| Genetic Vectors | 19 | 2016 | 446 | 2.210 |
Why?
|
| Vitamin D Deficiency | 8 | 2020 | 104 | 2.160 |
Why?
|
| Receptors, Progesterone | 9 | 2023 | 174 | 2.160 |
Why?
|
| Ovary | 6 | 2024 | 261 | 2.090 |
Why?
|
| MicroRNAs | 6 | 2023 | 551 | 2.040 |
Why?
|
| Apoptosis | 23 | 2024 | 1717 | 1.990 |
Why?
|
| Quality of Life | 20 | 2024 | 1668 | 1.980 |
Why?
|
| Gonadotropin-Releasing Hormone | 9 | 2024 | 108 | 1.960 |
Why?
|
| Steroids | 6 | 2023 | 174 | 1.930 |
Why?
|
| Extracellular Matrix | 6 | 2024 | 245 | 1.870 |
Why?
|
| Pregnancy | 27 | 2024 | 3018 | 1.800 |
Why?
|
| Receptors, Estrogen | 8 | 2020 | 393 | 1.800 |
Why?
|
| Cell Line, Tumor | 29 | 2024 | 2558 | 1.760 |
Why?
|
| Animals | 74 | 2024 | 27371 | 1.700 |
Why?
|
| Islam | 2 | 2024 | 36 | 1.660 |
Why?
|
| Stem Cells | 10 | 2023 | 372 | 1.650 |
Why?
|
| Fertility Preservation | 3 | 2024 | 23 | 1.610 |
Why?
|
| Norpregnadienes | 6 | 2024 | 9 | 1.610 |
Why?
|
| Regenerative Medicine | 2 | 2022 | 25 | 1.550 |
Why?
|
| Estrogen Receptor alpha | 7 | 2024 | 148 | 1.550 |
Why?
|
| Infertility, Female | 4 | 2020 | 97 | 1.520 |
Why?
|
| Reproduction | 4 | 2021 | 199 | 1.480 |
Why?
|
| Culture Media, Conditioned | 5 | 2024 | 103 | 1.440 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 5 | 2023 | 37 | 1.440 |
Why?
|
| Genital Diseases, Female | 4 | 2021 | 24 | 1.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2024 | 1265 | 1.380 |
Why?
|
| Biomarkers | 16 | 2023 | 1767 | 1.370 |
Why?
|
| Cholecalciferol | 5 | 2020 | 35 | 1.370 |
Why?
|
| DNA Repair | 5 | 2023 | 362 | 1.350 |
Why?
|
| Signal Transduction | 19 | 2024 | 3385 | 1.320 |
Why?
|
| Receptors, FSH | 6 | 2024 | 7 | 1.310 |
Why?
|
| Rats | 22 | 2023 | 4041 | 1.310 |
Why?
|
| Disease Models, Animal | 15 | 2024 | 2366 | 1.280 |
Why?
|
| Granulosa Cells | 3 | 2024 | 32 | 1.270 |
Why?
|
| Vitamins | 5 | 2020 | 83 | 1.240 |
Why?
|
| Genes, Reporter | 4 | 2023 | 275 | 1.230 |
Why?
|
| Mice | 36 | 2024 | 11761 | 1.190 |
Why?
|
| beta Catenin | 7 | 2023 | 266 | 1.160 |
Why?
|
| Transcription Factors | 4 | 2024 | 1653 | 1.160 |
Why?
|
| Progesterone | 8 | 2023 | 110 | 1.150 |
Why?
|
| Perimenopause | 2 | 2024 | 5 | 1.140 |
Why?
|
| Androgens | 3 | 2023 | 176 | 1.130 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2022 | 296 | 1.130 |
Why?
|
| Ovarian Follicle | 5 | 2021 | 72 | 1.110 |
Why?
|
| Neoplastic Stem Cells | 4 | 2024 | 162 | 1.080 |
Why?
|
| Tea | 5 | 2024 | 21 | 1.080 |
Why?
|
| Carcinogenesis | 4 | 2024 | 211 | 1.050 |
Why?
|
| Adult | 40 | 2024 | 26607 | 1.010 |
Why?
|
| Endometrium | 5 | 2016 | 50 | 1.000 |
Why?
|
| Proliferating Cell Nuclear Antigen | 9 | 2023 | 67 | 0.990 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2021 | 2340 | 0.980 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 2415 | 0.970 |
Why?
|
| Transduction, Genetic | 5 | 2013 | 160 | 0.970 |
Why?
|
| Gene Targeting | 3 | 2016 | 73 | 0.970 |
Why?
|
| Obstetrics | 3 | 2022 | 123 | 0.960 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2018 | 16 | 0.950 |
Why?
|
| Pyrimidines | 7 | 2022 | 374 | 0.940 |
Why?
|
| Gene Expression Regulation, Enzymologic | 5 | 2010 | 217 | 0.940 |
Why?
|
| Cells, Cultured | 15 | 2021 | 2884 | 0.930 |
Why?
|
| Thymidine Kinase | 4 | 2009 | 30 | 0.930 |
Why?
|
| Ovarian Neoplasms | 5 | 2021 | 764 | 0.910 |
Why?
|
| Premature Birth | 4 | 2017 | 117 | 0.900 |
Why?
|
| Gene Transfer Techniques | 5 | 2016 | 153 | 0.890 |
Why?
|
| RNA, Long Noncoding | 2 | 2022 | 117 | 0.880 |
Why?
|
| Tumor Cells, Cultured | 13 | 2020 | 1057 | 0.880 |
Why?
|
| Calcitriol | 3 | 2013 | 173 | 0.880 |
Why?
|
| Receptors, Calcitriol | 5 | 2015 | 130 | 0.870 |
Why?
|
| Pelvic Neoplasms | 1 | 2023 | 45 | 0.860 |
Why?
|
| Anemia | 1 | 2024 | 130 | 0.860 |
Why?
|
| Clomiphene | 2 | 2023 | 18 | 0.850 |
Why?
|
| Fertility | 5 | 2024 | 117 | 0.850 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 4 | 2011 | 9 | 0.840 |
Why?
|
| Hormone Antagonists | 3 | 2020 | 19 | 0.840 |
Why?
|
| Transfection | 14 | 2020 | 911 | 0.830 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 42 | 0.830 |
Why?
|
| Gynecology | 2 | 2024 | 129 | 0.820 |
Why?
|
| Hysterectomy | 5 | 2023 | 151 | 0.810 |
Why?
|
| Theca Cells | 1 | 2021 | 12 | 0.790 |
Why?
|
| Hyaluronan Receptors | 6 | 2018 | 38 | 0.780 |
Why?
|
| Air Pollution | 1 | 2023 | 92 | 0.770 |
Why?
|
| Air Pollutants | 1 | 2023 | 92 | 0.770 |
Why?
|
| Genitalia, Female | 1 | 2021 | 25 | 0.770 |
Why?
|
| Stem Cell Transplantation | 2 | 2022 | 188 | 0.760 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2021 | 48 | 0.760 |
Why?
|
| Adult Stem Cells | 2 | 2018 | 29 | 0.760 |
Why?
|
| Injections, Intra-Arterial | 1 | 2021 | 33 | 0.750 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2024 | 447 | 0.750 |
Why?
|
| Middle Aged | 25 | 2024 | 25974 | 0.750 |
Why?
|
| Mutation | 13 | 2024 | 4143 | 0.740 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 302 | 0.720 |
Why?
|
| Hydrocarbons, Fluorinated | 4 | 2021 | 14 | 0.710 |
Why?
|
| Molecular Probe Techniques | 1 | 2020 | 9 | 0.700 |
Why?
|
| Bone Marrow Cells | 2 | 2021 | 262 | 0.700 |
Why?
|
| Tissue Engineering | 1 | 2021 | 185 | 0.660 |
Why?
|
| Gene Expression | 10 | 2020 | 1310 | 0.640 |
Why?
|
| Pharmacokinetics | 1 | 2018 | 10 | 0.640 |
Why?
|
| Tissue Adhesions | 4 | 2016 | 50 | 0.630 |
Why?
|
| Simvastatin | 5 | 2022 | 105 | 0.630 |
Why?
|
| RNA, Small Untranslated | 1 | 2018 | 15 | 0.620 |
Why?
|
| Down-Regulation | 9 | 2020 | 519 | 0.620 |
Why?
|
| Antigens, Surface | 5 | 2018 | 103 | 0.610 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 2016 | 8 | 0.610 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 309 | 0.600 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 168 | 0.590 |
Why?
|
| Busulfan | 1 | 2017 | 41 | 0.580 |
Why?
|
| Endometrial Neoplasms | 3 | 2022 | 205 | 0.570 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2024 | 127 | 0.570 |
Why?
|
| Histones | 2 | 2016 | 329 | 0.570 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 273 | 0.570 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 200 | 0.560 |
Why?
|
| Drug Therapy, Combination | 7 | 2024 | 784 | 0.560 |
Why?
|
| Cell Compartmentation | 1 | 2016 | 69 | 0.560 |
Why?
|
| Drug Discovery | 1 | 2017 | 107 | 0.560 |
Why?
|
| Risk Factors | 12 | 2022 | 5499 | 0.550 |
Why?
|
| Yersinia enterocolitica | 6 | 1995 | 18 | 0.540 |
Why?
|
| Magnetite Nanoparticles | 1 | 2016 | 27 | 0.540 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 30 | 0.540 |
Why?
|
| Cell Cycle Proteins | 5 | 2024 | 401 | 0.530 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 838 | 0.530 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 55 | 0.530 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2018 | 1942 | 0.520 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 187 | 0.520 |
Why?
|
| Cell Line, Transformed | 6 | 2016 | 155 | 0.510 |
Why?
|
| Cyclin D1 | 6 | 2023 | 84 | 0.510 |
Why?
|
| Amenorrhea | 3 | 2023 | 28 | 0.510 |
Why?
|
| Wnt Proteins | 1 | 2016 | 130 | 0.500 |
Why?
|
| Rad51 Recombinase | 1 | 2016 | 80 | 0.500 |
Why?
|
| Ergocalciferols | 2 | 2015 | 38 | 0.500 |
Why?
|
| Hormones | 3 | 2023 | 139 | 0.500 |
Why?
|
| Mice, Nude | 8 | 2021 | 815 | 0.490 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1549 | 0.490 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2014 | 1 | 0.490 |
Why?
|
| Nails | 1 | 2014 | 7 | 0.490 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 433 | 0.490 |
Why?
|
| DNA Damage | 3 | 2023 | 371 | 0.490 |
Why?
|
| Cell Growth Processes | 2 | 2012 | 85 | 0.480 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 481 | 0.480 |
Why?
|
| Pregnancy Tests | 1 | 2014 | 2 | 0.470 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 204 | 0.470 |
Why?
|
| Krukenberg Tumor | 1 | 2014 | 3 | 0.470 |
Why?
|
| Cytokines | 5 | 2024 | 803 | 0.470 |
Why?
|
| Transforming Growth Factor beta | 4 | 2023 | 324 | 0.460 |
Why?
|
| Back Pain | 1 | 2014 | 42 | 0.460 |
Why?
|
| Cost of Illness | 4 | 2018 | 147 | 0.460 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2014 | 85 | 0.460 |
Why?
|
| Lipopolysaccharides | 5 | 1995 | 293 | 0.450 |
Why?
|
| Point Mutation | 2 | 2007 | 245 | 0.450 |
Why?
|
| Treatment Outcome | 11 | 2024 | 8241 | 0.450 |
Why?
|
| DNA, Recombinant | 1 | 2013 | 67 | 0.450 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 48 | 0.440 |
Why?
|
| Collagen | 4 | 2018 | 293 | 0.440 |
Why?
|
| Health Status Disparities | 2 | 2024 | 188 | 0.430 |
Why?
|
| Cervix Uteri | 3 | 2014 | 70 | 0.420 |
Why?
|
| Menstrual Cycle | 3 | 2016 | 54 | 0.420 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 699 | 0.410 |
Why?
|
| Fibroblasts | 2 | 2013 | 755 | 0.410 |
Why?
|
| Contractile Proteins | 1 | 2012 | 57 | 0.410 |
Why?
|
| Drug Combinations | 2 | 2024 | 203 | 0.410 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 540 | 0.410 |
Why?
|
| Infant, Newborn | 4 | 2023 | 2486 | 0.400 |
Why?
|
| Benzophenones | 2 | 2011 | 12 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 286 | 0.400 |
Why?
|
| Toll-Like Receptors | 1 | 2012 | 92 | 0.400 |
Why?
|
| Paracrine Communication | 1 | 2011 | 32 | 0.390 |
Why?
|
| Caspase 3 | 4 | 2023 | 162 | 0.390 |
Why?
|
| Luciferases | 4 | 2016 | 128 | 0.390 |
Why?
|
| Simplexvirus | 2 | 2006 | 151 | 0.390 |
Why?
|
| Double-Blind Method | 6 | 2021 | 1719 | 0.380 |
Why?
|
| Random Allocation | 5 | 2016 | 327 | 0.380 |
Why?
|
| Wnt Signaling Pathway | 3 | 2023 | 97 | 0.380 |
Why?
|
| Estrogens, Catechol | 2 | 2008 | 2 | 0.380 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 283 | 0.380 |
Why?
|
| Extraembryonic Membranes | 2 | 2014 | 8 | 0.370 |
Why?
|
| Hedgehog Proteins | 2 | 2021 | 100 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 340 | 0.360 |
Why?
|
| Adipocytes | 1 | 2011 | 162 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2014 | 196 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 242 | 0.360 |
Why?
|
| Cyclooxygenase 2 | 5 | 2017 | 99 | 0.350 |
Why?
|
| Menopause | 2 | 2020 | 76 | 0.350 |
Why?
|
| Protein Isoforms | 2 | 2007 | 275 | 0.340 |
Why?
|
| Up-Regulation | 7 | 2020 | 727 | 0.340 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 1799 | 0.340 |
Why?
|
| Dinoprostone | 1 | 2009 | 70 | 0.340 |
Why?
|
| Ganciclovir | 4 | 2009 | 49 | 0.340 |
Why?
|
| Models, Animal | 4 | 2020 | 277 | 0.340 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 73 | 0.330 |
Why?
|
| Labor, Obstetric | 1 | 2009 | 46 | 0.330 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 1976 | 0.320 |
Why?
|
| Pain Measurement | 2 | 2024 | 329 | 0.320 |
Why?
|
| Myocytes, Smooth Muscle | 3 | 2020 | 140 | 0.320 |
Why?
|
| Transcriptome | 2 | 2024 | 630 | 0.320 |
Why?
|
| Obstetric Labor, Premature | 2 | 2012 | 58 | 0.310 |
Why?
|
| Liver | 6 | 2023 | 1208 | 0.310 |
Why?
|
| Antioxidants | 1 | 2010 | 226 | 0.310 |
Why?
|
| Polymorphism, Genetic | 3 | 2008 | 825 | 0.310 |
Why?
|
| Transcription Factor RelA | 2 | 2020 | 49 | 0.310 |
Why?
|
| Drug Resistance, Multiple | 1 | 2008 | 20 | 0.310 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2023 | 46 | 0.310 |
Why?
|
| Microbiota | 2 | 2024 | 402 | 0.300 |
Why?
|
| Genital Neoplasms, Female | 1 | 2009 | 108 | 0.300 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2401 | 0.300 |
Why?
|
| Cell Differentiation | 3 | 2022 | 1525 | 0.290 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 47 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2014 | 30 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 157 | 0.290 |
Why?
|
| Germ Cells | 1 | 2007 | 130 | 0.280 |
Why?
|
| Antimitotic Agents | 1 | 2006 | 3 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1365 | 0.280 |
Why?
|
| Hot Flashes | 3 | 2021 | 12 | 0.280 |
Why?
|
| RNA, Messenger | 8 | 2014 | 2017 | 0.280 |
Why?
|
| Placenta | 2 | 2021 | 179 | 0.280 |
Why?
|
| Dexamethasone | 2 | 2020 | 344 | 0.270 |
Why?
|
| Environmental Exposure | 3 | 2020 | 322 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2009 | 424 | 0.260 |
Why?
|
| Berberine | 2 | 2016 | 8 | 0.260 |
Why?
|
| Interleukin-6 | 1 | 2007 | 261 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2021 | 377 | 0.260 |
Why?
|
| DNA Methylation | 3 | 2022 | 657 | 0.260 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1862 | 0.260 |
Why?
|
| Hemoglobins | 2 | 2024 | 192 | 0.260 |
Why?
|
| Antiviral Agents | 4 | 2009 | 478 | 0.260 |
Why?
|
| Bone Density | 3 | 2021 | 209 | 0.260 |
Why?
|
| DNA | 2 | 2023 | 1308 | 0.250 |
Why?
|
| Breast Neoplasms | 3 | 2008 | 3011 | 0.250 |
Why?
|
| Carboxylic Acids | 2 | 2022 | 17 | 0.250 |
Why?
|
| Growth Hormone | 2 | 1996 | 96 | 0.250 |
Why?
|
| Interferon-gamma | 1 | 2007 | 451 | 0.250 |
Why?
|
| Cell Survival | 4 | 2021 | 983 | 0.250 |
Why?
|
| Gene Silencing | 2 | 2017 | 178 | 0.250 |
Why?
|
| Uterus | 5 | 2020 | 222 | 0.250 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2024 | 9 | 0.250 |
Why?
|
| Rats, Mutant Strains | 2 | 2018 | 23 | 0.240 |
Why?
|
| NAD | 1 | 2024 | 72 | 0.240 |
Why?
|
| Azepines | 1 | 2024 | 25 | 0.240 |
Why?
|
| Mice, SCID | 3 | 2016 | 261 | 0.240 |
Why?
|
| Cell Line | 9 | 2018 | 2496 | 0.240 |
Why?
|
| Genes, Bacterial | 3 | 1995 | 198 | 0.230 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2024 | 66 | 0.230 |
Why?
|
| Serum Response Factor | 1 | 2024 | 45 | 0.230 |
Why?
|
| Benzodiazepines | 1 | 2024 | 67 | 0.230 |
Why?
|
| History, Medieval | 1 | 2024 | 12 | 0.230 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2024 | 11 | 0.230 |
Why?
|
| Pregnancy Rate | 1 | 2024 | 21 | 0.230 |
Why?
|
| Ovulation Induction | 1 | 2024 | 34 | 0.230 |
Why?
|
| Triazoles | 1 | 2024 | 102 | 0.230 |
Why?
|
| Standard of Care | 1 | 2024 | 65 | 0.230 |
Why?
|
| Uterine Hemorrhage | 1 | 2023 | 21 | 0.230 |
Why?
|
| Blotting, Western | 5 | 2014 | 794 | 0.220 |
Why?
|
| Peritoneal Diseases | 2 | 2016 | 16 | 0.220 |
Why?
|
| Tennessee | 2 | 2014 | 16 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 155 | 0.220 |
Why?
|
| Biological Assay | 1 | 2023 | 79 | 0.220 |
Why?
|
| Pregnancy Complications | 2 | 2016 | 345 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 887 | 0.220 |
Why?
|
| Umbilical Cord | 2 | 2021 | 40 | 0.220 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2023 | 72 | 0.220 |
Why?
|
| Probiotics | 1 | 2024 | 88 | 0.220 |
Why?
|
| Stromal Cells | 3 | 2016 | 151 | 0.220 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2024 | 43 | 0.220 |
Why?
|
| Symporters | 1 | 2023 | 108 | 0.220 |
Why?
|
| Life Style | 1 | 2024 | 172 | 0.220 |
Why?
|
| Fibronectins | 4 | 2018 | 101 | 0.220 |
Why?
|
| Secondary Prevention | 1 | 2023 | 158 | 0.210 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2023 | 44 | 0.210 |
Why?
|
| Brazil | 1 | 2023 | 74 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2023 | 93 | 0.210 |
Why?
|
| Time Factors | 5 | 2014 | 5338 | 0.210 |
Why?
|
| Cities | 1 | 2023 | 43 | 0.210 |
Why?
|
| Pregnancy, Animal | 2 | 2017 | 58 | 0.210 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 1157 | 0.210 |
Why?
|
| Epigenomics | 1 | 2023 | 103 | 0.210 |
Why?
|
| Exons | 3 | 2018 | 451 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1719 | 0.210 |
Why?
|
| Pre-Eclampsia | 2 | 2021 | 254 | 0.210 |
Why?
|
| Freedom | 1 | 2022 | 18 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 126 | 0.210 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2016 | 661 | 0.210 |
Why?
|
| United States | 6 | 2022 | 6989 | 0.200 |
Why?
|
| Genetic Testing | 1 | 2006 | 537 | 0.200 |
Why?
|
| Heterografts | 2 | 2020 | 102 | 0.200 |
Why?
|
| Religion and Medicine | 1 | 2024 | 124 | 0.200 |
Why?
|
| Transcriptional Activation | 3 | 2008 | 294 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 374 | 0.200 |
Why?
|
| Tumor Burden | 3 | 2018 | 308 | 0.200 |
Why?
|
| Sarcoma | 1 | 2024 | 220 | 0.200 |
Why?
|
| Fertility Agents, Female | 1 | 2021 | 3 | 0.200 |
Why?
|
| Recombinant Proteins | 3 | 2018 | 1012 | 0.200 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2014 | 85 | 0.200 |
Why?
|
| Ligands | 1 | 2023 | 445 | 0.200 |
Why?
|
| Research | 2 | 2020 | 252 | 0.200 |
Why?
|
| Evidence-Based Practice | 1 | 2022 | 48 | 0.200 |
Why?
|
| ortho-Aminobenzoates | 2 | 2020 | 4 | 0.200 |
Why?
|
| Young Adult | 6 | 2023 | 6312 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase 8 | 2 | 2018 | 2 | 0.200 |
Why?
|
| Mice, Knockout | 5 | 2015 | 2001 | 0.190 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 59 | 0.190 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 294 | 0.190 |
Why?
|
| Proteogenomics | 1 | 2021 | 5 | 0.190 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2018 | 43 | 0.190 |
Why?
|
| Fumarate Hydratase | 1 | 2021 | 6 | 0.190 |
Why?
|
| Gynatresia | 1 | 2021 | 1 | 0.190 |
Why?
|
| Menstruation | 1 | 2021 | 35 | 0.190 |
Why?
|
| Deficiency Diseases | 1 | 2021 | 12 | 0.190 |
Why?
|
| Platelet-Rich Plasma | 1 | 2021 | 11 | 0.190 |
Why?
|
| Cell Transplantation | 3 | 1996 | 47 | 0.190 |
Why?
|
| Amnion | 1 | 2021 | 15 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 135 | 0.190 |
Why?
|
| Cellular Reprogramming | 2 | 2018 | 41 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2021 | 18 | 0.190 |
Why?
|
| Nutrition Therapy | 1 | 2021 | 10 | 0.190 |
Why?
|
| Smoothened Receptor | 1 | 2020 | 6 | 0.190 |
Why?
|
| Pelvic Pain | 1 | 2022 | 84 | 0.190 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 20 | 0.190 |
Why?
|
| Exocytosis | 1 | 2021 | 109 | 0.190 |
Why?
|
| Mutant Proteins | 2 | 2014 | 96 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 1150 | 0.190 |
Why?
|
| Transforming Growth Factor beta3 | 3 | 2022 | 16 | 0.190 |
Why?
|
| Collagen Type I | 3 | 2017 | 72 | 0.190 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2013 | 198 | 0.190 |
Why?
|
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 4 | 0.190 |
Why?
|
| Cell Cycle | 4 | 2020 | 509 | 0.190 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2020 | 10 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2024 | 4289 | 0.190 |
Why?
|
| Uterine Artery Embolization | 2 | 2020 | 5 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 463 | 0.180 |
Why?
|
| Imidazoles | 1 | 2021 | 148 | 0.180 |
Why?
|
| Twins, Dizygotic | 1 | 2000 | 40 | 0.180 |
Why?
|
| Interleukin-10 | 1 | 2021 | 151 | 0.180 |
Why?
|
| Vitamin A | 1 | 2020 | 28 | 0.180 |
Why?
|
| Norethindrone | 1 | 2020 | 12 | 0.180 |
Why?
|
| Oxidative Stress | 2 | 2017 | 458 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 1574 | 0.180 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 1194 | 0.180 |
Why?
|
| Histone Deacetylase 1 | 1 | 2020 | 15 | 0.180 |
Why?
|
| Biopsy | 2 | 2014 | 1184 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 290 | 0.180 |
Why?
|
| Recurrence | 1 | 2023 | 1144 | 0.180 |
Why?
|
| Wnt4 Protein | 1 | 2020 | 4 | 0.180 |
Why?
|
| Mitochondria | 1 | 2024 | 553 | 0.180 |
Why?
|
| Histone Deacetylases | 2 | 2022 | 70 | 0.180 |
Why?
|
| Regeneration | 1 | 2021 | 150 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 956 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 132 | 0.170 |
Why?
|
| In Vitro Techniques | 3 | 2015 | 996 | 0.170 |
Why?
|
| Molecular Probes | 1 | 2020 | 35 | 0.170 |
Why?
|
| Disease Management | 1 | 2022 | 329 | 0.170 |
Why?
|
| Prognosis | 2 | 2024 | 3783 | 0.170 |
Why?
|
| Pyridines | 1 | 2021 | 315 | 0.170 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 499 | 0.170 |
Why?
|
| Smad Proteins | 2 | 2017 | 43 | 0.170 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 195 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2018 | 682 | 0.160 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 1991 | 213 | 0.160 |
Why?
|
| Proteins | 1 | 2024 | 787 | 0.160 |
Why?
|
| RNA | 1 | 2023 | 580 | 0.160 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2020 | 131 | 0.160 |
Why?
|
| Texas | 2 | 2018 | 113 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2021 | 259 | 0.160 |
Why?
|
| Leishmania donovani | 1 | 2018 | 3 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2016 | 226 | 0.160 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2018 | 5 | 0.160 |
Why?
|
| Contraceptive Agents, Female | 1 | 2018 | 31 | 0.160 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 66 | 0.160 |
Why?
|
| Cyclin C | 1 | 2018 | 1 | 0.160 |
Why?
|
| Receptors, Androgen | 2 | 2020 | 123 | 0.160 |
Why?
|
| Diethylstilbestrol | 1 | 2018 | 119 | 0.150 |
Why?
|
| Parity | 1 | 2018 | 96 | 0.150 |
Why?
|
| Growth Disorders | 2 | 1996 | 63 | 0.150 |
Why?
|
| Leuprolide | 1 | 2017 | 35 | 0.150 |
Why?
|
| Therapies, Investigational | 1 | 2017 | 17 | 0.150 |
Why?
|
| Autophagy | 1 | 2020 | 159 | 0.150 |
Why?
|
| Hydroxyestrones | 2 | 2007 | 4 | 0.150 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2017 | 44 | 0.150 |
Why?
|
| Models, Immunological | 1 | 2017 | 81 | 0.150 |
Why?
|
| Receptors, Virus | 2 | 2008 | 75 | 0.150 |
Why?
|
| Drug Design | 1 | 2017 | 127 | 0.150 |
Why?
|
| Ethanol | 1 | 2020 | 250 | 0.150 |
Why?
|
| Flow Cytometry | 3 | 2008 | 691 | 0.140 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2014 | 18 | 0.140 |
Why?
|
| Tumor Hypoxia | 1 | 2017 | 31 | 0.140 |
Why?
|
| Securin | 1 | 2016 | 2 | 0.140 |
Why?
|
| Enzyme Activation | 2 | 2010 | 698 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 14 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 509 | 0.140 |
Why?
|
| Doxorubicin | 2 | 2008 | 301 | 0.140 |
Why?
|
| Oxidoreductases | 1 | 2017 | 112 | 0.140 |
Why?
|
| Abruptio Placentae | 1 | 2016 | 13 | 0.140 |
Why?
|
| Cell Division | 2 | 2010 | 696 | 0.140 |
Why?
|
| Fetal Death | 1 | 2016 | 57 | 0.140 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 1431 | 0.140 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 27 | 0.140 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 108 | 0.140 |
Why?
|
| Cell Count | 1 | 2016 | 200 | 0.140 |
Why?
|
| Hydatidiform Mole | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2016 | 4 | 0.130 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2011 | 122 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 895 | 0.130 |
Why?
|
| Antibodies | 1 | 2018 | 353 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1723 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2016 | 43 | 0.130 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 51 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 580 | 0.130 |
Why?
|
| Benzo(a)pyrene | 1 | 2015 | 5 | 0.130 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 7 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 344 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 267 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2017 | 235 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2016 | 169 | 0.130 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2015 | 6 | 0.130 |
Why?
|
| Keratin-19 | 1 | 2015 | 10 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 445 | 0.120 |
Why?
|
| Coculture Techniques | 2 | 2013 | 174 | 0.120 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2014 | 5 | 0.120 |
Why?
|
| Oxygen | 2 | 2017 | 743 | 0.120 |
Why?
|
| Ascitic Fluid | 2 | 2008 | 38 | 0.120 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2016 | 152 | 0.120 |
Why?
|
| Placentation | 1 | 2014 | 11 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 100 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2022 | 1047 | 0.120 |
Why?
|
| bcl-Associated Death Protein | 1 | 2014 | 16 | 0.120 |
Why?
|
| Hirsutism | 1 | 2014 | 61 | 0.120 |
Why?
|
| Genes, myc | 1 | 2014 | 39 | 0.120 |
Why?
|
| Hyperandrogenism | 1 | 2014 | 43 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2008 | 618 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2015 | 158 | 0.120 |
Why?
|
| Postmenopause | 1 | 2014 | 102 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2014 | 223 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 428 | 0.110 |
Why?
|
| Enzyme Precursors | 1 | 2013 | 21 | 0.110 |
Why?
|
| Age Factors | 1 | 2018 | 1870 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 645 | 0.110 |
Why?
|
| Catalase | 1 | 2013 | 49 | 0.110 |
Why?
|
| NADPH Oxidases | 1 | 2014 | 82 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 2015 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 179 | 0.110 |
Why?
|
| Women's Health | 1 | 2014 | 102 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2013 | 24 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2014 | 299 | 0.110 |
Why?
|
| Osmolar Concentration | 1 | 2013 | 181 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 22 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2014 | 192 | 0.110 |
Why?
|
| Gastroparesis | 1 | 2013 | 14 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 277 | 0.110 |
Why?
|
| Male | 12 | 2024 | 42411 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2014 | 277 | 0.110 |
Why?
|
| Muscle Contraction | 1 | 2013 | 284 | 0.110 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 1 | 2012 | 1 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2016 | 171 | 0.100 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2012 | 15 | 0.100 |
Why?
|
| Dizziness | 1 | 2012 | 26 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 557 | 0.100 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 177 | 0.100 |
Why?
|
| Child | 1 | 2024 | 7174 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2017 | 945 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 433 | 0.100 |
Why?
|
| Aging | 1 | 2016 | 718 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 529 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2012 | 134 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 645 | 0.100 |
Why?
|
| Multigene Family | 2 | 1993 | 203 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 866 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 601 | 0.090 |
Why?
|
| Connexin 43 | 2 | 2013 | 94 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 345 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2022 | 92 | 0.090 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2008 | 24 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 120 | 0.090 |
Why?
|
| Phosphorylation | 4 | 2015 | 1132 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3666 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 315 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2017 | 1374 | 0.090 |
Why?
|
| CDC2 Protein Kinase | 1 | 2010 | 46 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2013 | 466 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 470 | 0.090 |
Why?
|
| Internship and Residency | 1 | 1999 | 1045 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 123 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 319 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 565 | 0.090 |
Why?
|
| Camellia sinensis | 1 | 2009 | 7 | 0.090 |
Why?
|
| Phenotype | 3 | 2021 | 2440 | 0.090 |
Why?
|
| Calcium | 1 | 2014 | 1175 | 0.090 |
Why?
|
| Haplotypes | 1 | 2012 | 637 | 0.090 |
Why?
|
| Base Sequence | 3 | 2007 | 2327 | 0.080 |
Why?
|
| Infant, Premature | 1 | 2011 | 298 | 0.080 |
Why?
|
| Liver Regeneration | 1 | 2009 | 36 | 0.080 |
Why?
|
| Rats, Wistar | 3 | 2016 | 302 | 0.080 |
Why?
|
| Prevalence | 2 | 2018 | 1243 | 0.080 |
Why?
|
| Oxidation-Reduction | 2 | 2024 | 388 | 0.080 |
Why?
|
| Capsid Proteins | 1 | 2008 | 32 | 0.080 |
Why?
|
| Glucuronidase | 1 | 2008 | 23 | 0.080 |
Why?
|
| Neoplastic Processes | 1 | 2008 | 1 | 0.080 |
Why?
|
| beta-Galactosidase | 1 | 2008 | 73 | 0.080 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 66 | 0.080 |
Why?
|
| Rhodamine 123 | 1 | 2008 | 8 | 0.080 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2008 | 18 | 0.080 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2008 | 47 | 0.080 |
Why?
|
| Lewis X Antigen | 1 | 2007 | 9 | 0.080 |
Why?
|
| Estriol | 1 | 2007 | 8 | 0.080 |
Why?
|
| Finland | 1 | 2007 | 28 | 0.080 |
Why?
|
| Cervical Ripening | 1 | 2007 | 4 | 0.080 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2007 | 10 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 88 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2016 | 2284 | 0.070 |
Why?
|
| Mifepristone | 1 | 2007 | 34 | 0.070 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2007 | 147 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 988 | 0.070 |
Why?
|
| COS Cells | 1 | 2007 | 167 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 80 | 0.070 |
Why?
|
| DNA, Antisense | 1 | 2007 | 15 | 0.070 |
Why?
|
| Dihydrotestosterone | 1 | 2007 | 28 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2007 | 726 | 0.070 |
Why?
|
| Ovulation | 1 | 2007 | 68 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2009 | 245 | 0.070 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2007 | 64 | 0.070 |
Why?
|
| Genes, Dominant | 1 | 2007 | 117 | 0.070 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2007 | 12 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 116 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2007 | 86 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 117 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 112 | 0.070 |
Why?
|
| Pregnancy Proteins | 1 | 2007 | 38 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2018 | 66 | 0.070 |
Why?
|
| Cyclic AMP | 1 | 2007 | 274 | 0.070 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2006 | 31 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2008 | 370 | 0.070 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2006 | 34 | 0.070 |
Why?
|
| Bystander Effect | 1 | 2006 | 12 | 0.070 |
Why?
|
| Interleukin-15 | 1 | 2007 | 73 | 0.070 |
Why?
|
| Human papillomavirus 16 | 1 | 2006 | 38 | 0.070 |
Why?
|
| Tretinoin | 1 | 2007 | 128 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 2007 | 251 | 0.070 |
Why?
|
| Muscle, Smooth | 2 | 2020 | 354 | 0.070 |
Why?
|
| Piperidines | 2 | 2024 | 166 | 0.070 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 244 | 0.070 |
Why?
|
| Acetylcysteine | 1 | 2006 | 70 | 0.070 |
Why?
|
| DNA Primers | 1 | 2007 | 543 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2006 | 51 | 0.070 |
Why?
|
| Drug Compounding | 3 | 1996 | 81 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 711 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 364 | 0.070 |
Why?
|
| Swine | 1 | 2007 | 582 | 0.060 |
Why?
|
| Cloning, Molecular | 3 | 1991 | 646 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 922 | 0.060 |
Why?
|
| Temperature | 3 | 1991 | 404 | 0.060 |
Why?
|
| Muscles | 2 | 1996 | 193 | 0.060 |
Why?
|
| Dietary Supplements | 2 | 2016 | 125 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 1237 | 0.060 |
Why?
|
| Acrylamides | 1 | 2024 | 34 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2016 | 2303 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1840 | 0.060 |
Why?
|
| Niacinamide | 1 | 2024 | 117 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 2624 | 0.060 |
Why?
|
| Amyloidogenic Proteins | 1 | 2024 | 14 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 181 | 0.060 |
Why?
|
| Spermatogonia | 1 | 2023 | 13 | 0.060 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2016 | 43 | 0.060 |
Why?
|
| Cytosol | 2 | 2014 | 193 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2024 | 59 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2661 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2007 | 773 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 261 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2006 | 423 | 0.060 |
Why?
|
| Microglia | 1 | 2024 | 107 | 0.050 |
Why?
|
| DNA Transposable Elements | 2 | 1995 | 175 | 0.050 |
Why?
|
| Receptors, LHRH | 1 | 2022 | 4 | 0.050 |
Why?
|
| Adolescent | 3 | 2023 | 9263 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 92 | 0.050 |
Why?
|
| Folic Acid | 1 | 2023 | 63 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2016 | 89 | 0.050 |
Why?
|
| Dysmenorrhea | 1 | 2023 | 53 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 62 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2022 | 78 | 0.050 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2021 | 21 | 0.050 |
Why?
|
| Lipoylation | 1 | 2021 | 30 | 0.050 |
Why?
|
| Sulfones | 1 | 2021 | 45 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 1242 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 1088 | 0.050 |
Why?
|
| Vagina | 1 | 2022 | 173 | 0.050 |
Why?
|
| Lactation | 1 | 2021 | 54 | 0.050 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2020 | 21 | 0.050 |
Why?
|
| Genotype | 1 | 2006 | 1849 | 0.050 |
Why?
|
| Proteolysis | 1 | 2021 | 110 | 0.050 |
Why?
|
| North Carolina | 1 | 2020 | 50 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2021 | 80 | 0.050 |
Why?
|
| Asparagine | 1 | 2000 | 30 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 1991 | 258 | 0.050 |
Why?
|
| Threonine | 1 | 2000 | 35 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1991 | 269 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 490 | 0.050 |
Why?
|
| Body Weight | 2 | 2008 | 452 | 0.040 |
Why?
|
| Alanine | 1 | 2000 | 83 | 0.040 |
Why?
|
| Codon | 1 | 2000 | 122 | 0.040 |
Why?
|
| Period Circadian Proteins | 1 | 2020 | 10 | 0.040 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2020 | 9 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2000 | 26 | 0.040 |
Why?
|
| Adenine | 1 | 2000 | 88 | 0.040 |
Why?
|
| Models, Biological | 1 | 2007 | 1765 | 0.040 |
Why?
|
| Serine | 1 | 2000 | 104 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 38 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 1489 | 0.040 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2020 | 15 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 76 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 51 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2020 | 284 | 0.040 |
Why?
|
| Protein Transport | 1 | 2021 | 421 | 0.040 |
Why?
|
| Headache | 1 | 2020 | 72 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 207 | 0.040 |
Why?
|
| Guanine | 1 | 2000 | 207 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 308 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 112 | 0.040 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 14 | 0.040 |
Why?
|
| Transforming Growth Factors | 1 | 2019 | 12 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 599 | 0.040 |
Why?
|
| North America | 1 | 1999 | 184 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 397 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2013 | 9057 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2008 | 689 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2019 | 77 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 2000 | 624 | 0.040 |
Why?
|
| Nausea | 1 | 2020 | 176 | 0.040 |
Why?
|
| Enzyme Assays | 1 | 2018 | 16 | 0.040 |
Why?
|
| Alginates | 2 | 1996 | 16 | 0.040 |
Why?
|
| Polylysine | 2 | 1996 | 34 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2022 | 385 | 0.040 |
Why?
|
| Operon | 2 | 1995 | 49 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2020 | 599 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2000 | 309 | 0.040 |
Why?
|
| Bacterial Proteins | 2 | 1995 | 892 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2018 | 67 | 0.040 |
Why?
|
| Escherichia coli | 2 | 1991 | 605 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 2566 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2017 | 17 | 0.040 |
Why?
|
| Receptors, Leptin | 1 | 2017 | 32 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1995 | 418 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 157 | 0.040 |
Why?
|
| Peroxidase | 1 | 2017 | 51 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2017 | 88 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 784 | 0.040 |
Why?
|
| Adenovirus E4 Proteins | 1 | 2016 | 1 | 0.040 |
Why?
|
| Instillation, Drug | 1 | 2016 | 3 | 0.040 |
Why?
|
| Hemophilia B | 1 | 1996 | 4 | 0.030 |
Why?
|
| Factor IX | 1 | 1996 | 4 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3448 | 0.030 |
Why?
|
| Growth | 1 | 1996 | 43 | 0.030 |
Why?
|
| Toxicokinetics | 1 | 2015 | 1 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 325 | 0.030 |
Why?
|
| Biotransformation | 1 | 2015 | 50 | 0.030 |
Why?
|
| Serotyping | 1 | 1995 | 28 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2015 | 49 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1995 | 97 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2016 | 138 | 0.030 |
Why?
|
| Progestins | 1 | 2015 | 22 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 2015 | 8 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1996 | 114 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 293 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2016 | 127 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1997 | 487 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 2015 | 48 | 0.030 |
Why?
|
| Bacteriophages | 1 | 1995 | 52 | 0.030 |
Why?
|
| Carbon Tetrachloride | 1 | 2014 | 6 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1995 | 68 | 0.030 |
Why?
|
| Bone Development | 1 | 1995 | 36 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 2014 | 33 | 0.030 |
Why?
|
| Calcium Channels, L-Type | 1 | 2014 | 38 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1995 | 290 | 0.030 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2014 | 32 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2015 | 274 | 0.030 |
Why?
|
| Salmonella typhimurium | 2 | 1993 | 32 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 871 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 1995 | 243 | 0.030 |
Why?
|
| Chelating Agents | 1 | 2014 | 69 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 1995 | 2062 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2014 | 22 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 2 | 1993 | 112 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 595 | 0.030 |
Why?
|
| Receptors, Prostaglandin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Organ Size | 1 | 1995 | 371 | 0.030 |
Why?
|
| Receptors, Oxytocin | 1 | 2013 | 10 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2013 | 42 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 54 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 198 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 1996 | 996 | 0.030 |
Why?
|
| Deoxy Sugars | 1 | 1993 | 3 | 0.030 |
Why?
|
| Hexoses | 1 | 1993 | 4 | 0.030 |
Why?
|
| Salmonella | 1 | 1993 | 14 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2014 | 161 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 3027 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 1995 | 198 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1993 | 32 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2013 | 25 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 428 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 282 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 170 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 682 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 1992 | 149 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 1996 | 3218 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 432 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 899 | 0.020 |
Why?
|
| Hypoxia | 1 | 2017 | 653 | 0.020 |
Why?
|
| Actins | 1 | 2014 | 458 | 0.020 |
Why?
|
| Fractional Precipitation | 1 | 1991 | 1 | 0.020 |
Why?
|
| Yersinia | 1 | 1991 | 2 | 0.020 |
Why?
|
| Agglutination Tests | 1 | 1991 | 11 | 0.020 |
Why?
|
| Silver | 1 | 1991 | 16 | 0.020 |
Why?
|
| Virulence | 1 | 1992 | 280 | 0.020 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1991 | 25 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1991 | 156 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1991 | 65 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 243 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 105 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1991 | 168 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1991 | 273 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1996 | 1070 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 323 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 291 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1066 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 234 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 950 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 101 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 72 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 75 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2009 | 37 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 132 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 240 | 0.020 |
Why?
|
| Physicians | 1 | 2016 | 690 | 0.020 |
Why?
|
| Chromatography, Micellar Electrokinetic Capillary | 1 | 2008 | 2 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2008 | 49 | 0.020 |
Why?
|
| Dogs | 1 | 2009 | 704 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 106 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 104 | 0.020 |
Why?
|
| Collagen Type III | 1 | 2007 | 4 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 1076 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2007 | 21 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 306 | 0.020 |
Why?
|
| Consciousness | 1 | 2007 | 28 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1488 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2007 | 72 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 192 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 479 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 353 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 618 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 661 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 317 | 0.020 |
Why?
|
| Environment | 1 | 2006 | 223 | 0.020 |
Why?
|
| Myocardium | 1 | 2008 | 571 | 0.020 |
Why?
|
| Tocopherols | 1 | 2004 | 6 | 0.010 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2004 | 16 | 0.010 |
Why?
|
| Quinazolinones | 1 | 2004 | 15 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 73 | 0.010 |
Why?
|
| Pyridones | 1 | 2004 | 56 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2004 | 226 | 0.010 |
Why?
|
| Heparin | 1 | 2004 | 185 | 0.010 |
Why?
|
| Quinazolines | 1 | 2004 | 221 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 745 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 1877 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1996 | 10 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1996 | 11 | 0.010 |
Why?
|
| Antibodies, Heterophile | 1 | 1996 | 20 | 0.010 |
Why?
|
| Nucleoside Diphosphate Sugars | 1 | 1993 | 4 | 0.010 |
Why?
|
| Thymine Nucleotides | 1 | 1993 | 6 | 0.010 |
Why?
|
| O Antigens | 1 | 1993 | 12 | 0.010 |
Why?
|
| Neisseria meningitidis | 1 | 1993 | 8 | 0.010 |
Why?
|
| Haemophilus influenzae | 1 | 1993 | 15 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1993 | 353 | 0.010 |
Why?
|
| Species Specificity | 1 | 1993 | 684 | 0.010 |
Why?
|